South San Francisco, CA, October 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via webcast and in virtual one-on-one meetings. Please see additional details below:
Credit Suisse 30th Annual Healthcare Conference
Date: Wednesday, November 10th
Time: 3:30 to 4:10 p.m. ET (virtual event)
Presenter: John Kollins, President & CEO of Satsuma Pharmaceuticals
Webcast: Registration Link – Click Her
* a replay will be available following the presentation
Please contact your representative at Credit Suisse to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference
For more information about the Credit Suisse 30th Annual Healthcare Conference, please refer to the conference website.
Evercore ISI 4th Annual HealthCONx Conference
Date: Tuesday, November 30th
Time: 11:20 to 11:40 a.m. ET (virtual event)
Presenter: John Kollins, President & CEO of Satsuma Pharmaceuticals
Webcast: Registration Link – Click Her
* a replay will be available following the presentation
Please contact your representative at Evercore ISI to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.
For more information about the Evercore ISI 4th Annual HealthCONx Conference, please refer to the Evercore ISI conference website.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. STS101 also now incorporates an improved 2nd-generation nasal delivery device designed to provide more consistent nasal dosing, irrespective of user administration technique. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com